ARGX vs TARS
argenx SE vs Tarsus Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
TARS
Tarsus Pharmaceuticals, Inc.
63
Buy
| Metric | ARGX | TARS |
|---|
| AI Score |
69
|
63
|
| Price |
$864.40
|
$69.50
|
| P/E Ratio |
31.34×
|
-63.72×
|
| ROE |
17.6%
|
-19.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
90.6%
|
| Debt / Equity |
0.01×
|
0.26×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
80.7
|
| Beta |
-0.022
|
0.512
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus TARS.
ARGX leads by 6 points.
ARGX scores 69/100 (Buy) versus TARS at 63/100 (Buy).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
TARS Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 105.2% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.21) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 10.1x prices in significant intangible value — Value
- ROE of only -13.5% -- cheap may mean cheap for a reason — Value
- RSI at 81 is in overbought territory — Technical